Kymera Therapeutics (KYMR) PT Raised to $39 at Credit Suisse
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- Wall Street ends higher on revived AI momentum
- Meta's $97.5B AI money grab: why Zuckerberg is racing to raise cash before rivals
- Deutsche Bank’s Reid sees potential final dip this year before Santa rally
- UPS tops estimates as efficiency drive gains momentum
- GM to move stock listing to Nasdaq in November, shares gain
Tweet
Share
E-mailGet Alerts KYMR Hot Sheet
Price: $117.57 +2.38%
Rating Summary:
26 Buy, 4 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 18
Rating Summary:
26 Buy, 4 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 18
Join SI Premium – FREE
Credit Suisse analyst Richard Law raised the price target on Kymera Therapeutics (NASDAQ: KYMR) to $39.00 (from $32.00) while maintaining a Neutral rating.
You May Also Be Interested In
- Kymera Therapeutics (KYMR) PT Raised to $146 at Morgan Stanley
- Itron (ITRI) PT Lowered to $105 at BNP Paribas Exane
- Travel + Leisure (TNL) PT Raised to $91 at Stifel
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
